JP2020501513A5 - - Google Patents

Download PDF

Info

Publication number
JP2020501513A5
JP2020501513A5 JP2019517069A JP2019517069A JP2020501513A5 JP 2020501513 A5 JP2020501513 A5 JP 2020501513A5 JP 2019517069 A JP2019517069 A JP 2019517069A JP 2019517069 A JP2019517069 A JP 2019517069A JP 2020501513 A5 JP2020501513 A5 JP 2020501513A5
Authority
JP
Japan
Prior art keywords
peptide
seq
construct
toxin
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501513A (ja
JP7133225B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2017/051094 external-priority patent/WO2018061004A1/en
Publication of JP2020501513A publication Critical patent/JP2020501513A/ja
Publication of JP2020501513A5 publication Critical patent/JP2020501513A5/ja
Application granted granted Critical
Publication of JP7133225B2 publication Critical patent/JP7133225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019517069A 2016-09-29 2017-09-27 治療用多標的コンストラクトおよびその使用 Active JP7133225B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662401192P 2016-09-29 2016-09-29
US201662401195P 2016-09-29 2016-09-29
US62/401,192 2016-09-29
US62/401,195 2016-09-29
PCT/IL2017/051094 WO2018061004A1 (en) 2016-09-29 2017-09-27 Therapeutic multi-targeting constructs and uses thereof

Publications (3)

Publication Number Publication Date
JP2020501513A JP2020501513A (ja) 2020-01-23
JP2020501513A5 true JP2020501513A5 (cg-RX-API-DMAC7.html) 2020-11-12
JP7133225B2 JP7133225B2 (ja) 2022-09-08

Family

ID=61763358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517069A Active JP7133225B2 (ja) 2016-09-29 2017-09-27 治療用多標的コンストラクトおよびその使用

Country Status (8)

Country Link
US (2) US11739163B2 (cg-RX-API-DMAC7.html)
EP (1) EP3518953A4 (cg-RX-API-DMAC7.html)
JP (1) JP7133225B2 (cg-RX-API-DMAC7.html)
CN (1) CN109789183A (cg-RX-API-DMAC7.html)
AU (2) AU2017333442A1 (cg-RX-API-DMAC7.html)
CA (1) CA3037261A1 (cg-RX-API-DMAC7.html)
IL (1) IL265236B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018061004A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
US20210198319A1 (en) * 2017-09-27 2021-07-01 Aebi Ltd. Cytotoxic peptides and conjugates thereof
KR102268983B1 (ko) 2019-09-11 2021-06-24 경북대학교 산학협력단 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도
CN112252362A (zh) * 2020-10-10 2021-01-22 无锡市市政设施建设工程有限公司 基于bim实现地铁车站主体结构盘扣支架搭设的方法
CN121494980A (zh) * 2025-12-12 2026-02-10 北京大学第一医院(北京大学第一临床医学院) 抗胃泌素抗体及其杂交瘤细胞株和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058865A1 (en) 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
ES2557286T3 (es) 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
DK1915617T3 (da) 2005-07-21 2011-11-21 Aebi Ltd Fremgangsmåder og sammensætninger til identifikation af et peptid, der har en intermolekylær interaktion med et interessemål
US20100021473A1 (en) 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
ES2544954T3 (es) 2006-02-14 2015-09-07 Universita' Degli Studi Di Siena Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
WO2008079973A2 (en) * 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
EP2352522A4 (en) 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Egfrを標的にした新規抗がんキメラペプチド
US8741839B2 (en) 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
US9321820B2 (en) 2009-10-14 2016-04-26 The Regents Of The University Of Colorado Compositions and methods for treating bladder cancer
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
CA2865243A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Egfr結合性ペプチド
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
WO2015010094A1 (en) 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
WO2015195721A1 (en) 2014-06-16 2015-12-23 Purdue Research Foundation Compositions and methods for treating cancer
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
US20210198319A1 (en) 2017-09-27 2021-07-01 Aebi Ltd. Cytotoxic peptides and conjugates thereof
US20200339629A1 (en) 2019-04-24 2020-10-29 Aebi Ltd. Therapeutic constructs comprising cmet binding peptides

Similar Documents

Publication Publication Date Title
ES2953482T3 (es) Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica
Teesalu et al. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Shin et al. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy
CN103965363B (zh) 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
JP2021502810A5 (cg-RX-API-DMAC7.html)
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
ES2926511T3 (es) Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos
EP3091028A1 (en) Fibronectin based scaffold proteins having improved stability
JP2021508449A5 (cg-RX-API-DMAC7.html)
RU2012147960A (ru) Trail r2-специфические мультимерные скаффолды
Zhang et al. Functional antibody CDR3 fusion proteins with enhanced pharmacological properties
JP2013541335A5 (cg-RX-API-DMAC7.html)
CN107223136B (zh) 一种将抗体导入细胞内的方法
US11377501B2 (en) Peptide having high affinity for PD-L1 protein and use thereof
JP2019501973A5 (cg-RX-API-DMAC7.html)
CN117924516B (zh) 一种提高adc药物疗效的重组蛋白及其应用
Song et al. Arginines in the CDR of anti‐dsDNA autoantibodies facilitate cell internalization via electrostatic interactions
JP2023528454A5 (cg-RX-API-DMAC7.html)
CN112641953A (zh) 一种靶向功能分子修饰的抗体复合物
Zhang et al. Human Serum Albumin‐Based Drug‐Free Macromolecular Therapeutics: Apoptosis Induction by Coiled‐Coil‐Mediated Cross‐Linking of CD20 Antigens on Lymphoma B Cell Surface
CN113444182A (zh) 一种靶向递送IgG类抗体的融合蛋白载体及其用途
JP2020501513A (ja) 治療用多標的コンストラクトおよびその使用
Liu et al. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity
Nyesiga et al. Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform
Ren et al. A SynB1-conjugated antibody cocktail crosses the blood–brain barrier to produce a therapeutic effect on rabies